Suspension of trading
Valuation Intra-Cellular Therapies, Inc.
Stocks
ITCI
US46116X1019
Pharmaceuticals
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 131.87 USD | -0.04% |
|
-.--% | - |
| 25-04-15 | J&J Boosts Outlook Despite Incoming Tariff Costs -- Update | DJ |
| 25-04-15 | J&J Increases Outlook After Beating 1Q Expectations | DJ |
Company Valuation: Intra-Cellular Therapies, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,896 | 2,549 | 4,264 | 5,012 | 6,893 | 8,855 |
| Change | - | 34.44% | 67.27% | 17.54% | 37.53% | 28.47% |
| Enterprise Value (EV) 1 | 1,695 | 1,921 | 3,877 | 4,440 | 6,412 | 7,870 |
| Change | - | 13.31% | 101.85% | 14.52% | 44.41% | 22.75% |
| P/E | -12.8x | -9.86x | -15x | -19.4x | -49.2x | -115x |
| PBR | 9.77x | 3.9x | 10.3x | 7.65x | 11.7x | 7.73x |
| PEG | - | -0.5x | -1.79x | 0.9x | 1.1x | 2.3x |
| Capitalization / Revenue | 31,281x | 112x | 50.9x | 20x | 14.8x | 13x |
| EV / Revenue | 27,967x | 84.2x | 46.3x | 17.7x | 13.8x | 11.6x |
| EV / EBITDA | -11x | -8.33x | -13.6x | -16.9x | -40.4x | -67.7x |
| EV / EBIT | -11x | -8.31x | -13.6x | -16.8x | -40.2x | -67.4x |
| EV / FCF | -22x | -12.9x | -25.8x | -24.6x | -221x | -124x |
| FCF Yield | -4.55% | -7.75% | -3.87% | -4.07% | -0.45% | -0.81% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -2.677 | -3.226 | -3.497 | -2.725 | -1.457 | -0.7241 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.0606 | 22.81 | 83.8 | 250.3 | 464.4 | 680.9 |
| EBITDA 1 | -153.5 | -230.7 | -285.2 | -263 | -158.9 | -116.2 |
| EBIT 1 | -154 | -231.2 | -285.7 | -263.6 | -159.4 | -116.7 |
| Net income 1 | -147.7 | -227 | -284.1 | -256.3 | -139.7 | -74.68 |
| Net Debt 1 | -200.9 | -628.3 | -386.9 | -571.9 | -481 | -984.1 |
| Reference price 2 | 34.31 | 31.80 | 52.34 | 52.92 | 71.62 | 83.52 |
| Nbr of stocks (in thousands) | 55,261 | 80,158 | 81,463 | 94,705 | 96,238 | 106,017 |
| Announcement Date | 3/2/20 | 2/25/21 | 3/1/22 | 3/1/23 | 2/22/24 | 2/21/25 |
1USD in Million2USD
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 14.02B | |
| 16.82x | 3.66x | 9.83x | 0.6% | 66.11B | |
| 27.43x | 5.64x | 16.57x | 0.58% | 55.3B | |
| 34.85x | 11.81x | 22.36x | -.--% | 42.44B | |
| -46.4x | 3.26x | 9.63x | 3.31% | 41.28B | |
| -9.48x | 13.79x | -8.46x | -.--% | 32.46B | |
| 31.76x | 3.6x | 11.15x | -.--% | 30.78B | |
| 16.78x | 3.2x | 9.7x | -.--% | 23.1B | |
| 56.99x | 6.38x | 44.22x | -.--% | 20.06B | |
| 26.81x | 5.49x | 14.75x | -.--% | 17.19B | |
| Average | 17.28x | 6.31x | 14.42x | 0.5% | 34.27B | |
| Weighted average by Cap. | 14.77x | 6.22x | 13.22x | 0.63% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ITCI Stock
- Valuation Intra-Cellular Therapies, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
